Member Info for avctIPmatters

Go for Monday 9th March .

Gmcc

FYI

"View Craig Foster’s graphic link

Craig FosterCraig Foster

• 3rd+Verified • 3rd+

CEO/Founder of Ondo Plc - Inventor of LeakBot and first InsurTech to IPO in EuropeCEO/Founder of Ondo Plc - Inventor of LeakBot and first InsurTech to IPO in Europe

1d • 1 day ago • Visible to anyone on or off LinkedIn

Follow

Selective Insurance started with a single-state LeakBot pilot in 2024.

This week we announced the next step: Selective is expanding the programme across its full 15-state Personal Lines footprint.

For us, that progression matters. Not because of the press release, but because it reflects something we’re seeing consistently across insurers....

This morning in Nashville I hosted a panel at the IoT Observatory with leaders from Nationwide, Indiana Farm Bureau Insurance, and The Hanover Insurance Group Insurance Group about what actually makes a prevention programme work at scale.

Different companies.

Different geographies.

Very similar conclusions.

Three themes came up again and again:

1. hashtag#LeakBot Customer satisfaction is extremely high

Homeowners value the combination of early detection and someone actually fixing the problem.

2. The plumbing model matters

Our W-2 employed plumber network turns a sensor into a real service. That operational layer is often the difference between “detecting leaks” and actually preventing claims.

3. Claims teams recognise the leak profile

The leaks LeakBot finds and fixes are exactly the slow, hidden failures that drive a large share of the roughly $17bn annual non-weather water damage problem for US insurers.

That alignment is what makes prevention credible.

When a pilot expands from one state to fifteen, it usually means something simple: The data matched the theory.

Selective has been an outstanding partner in testing and refining how these programmes should work, from customer engagement through to claims impact.

Good to see that work now scaling across their business."

Gmcc

More Avacta coverage courtesy Stonks ;

#AVCT's Enhertu comparison featured in the latest Next Generation Therapeutics Roundup from California-based pharma consultancy DeciBio.

https://www.decibio.com/insights/next-generation-therapeutics-february-round-up-2026

https://x.com/JStonker/status/2029657959865704696/photo/1

-----------

"Avacta Therapeutics Demonstrates Favorable Payload Delivery Compared to Enhertu | Clinical Trial

Avacta reported new preclinical data showing that its pre|CISION FAP-Exd (AVA6103) mechanism delivers a more favorable tumor-targeting profile than the marketed ADC Enhertu (trastuzumab deruxtecan, T-Dxd), using an AI-generated synthetic comparator arm based on published AstraZeneca nonclinical data. The analysis in a FAP-high animal model indicates three pharmacokinetic advantages for FAP-Exd versus T-Dxd: more rapid drug penetration into the tumor with tumor Cmax reached within minutes rather than 24 hours,, and a nearly three-fold higher Tumor Selectivity Index over 14 days. Avacta’s scientists also observed higher activity of FAP-Exd in tumor models with the lowest FAP expression compared with variable activity of T-Dxd at low HER2 expression levels, along with deep, durable responses persisting for many weeks after a three-dose regimen. CEO Christina Coughlin said this data suggests pre|CISION may offer important advantages over ADC mechanisms, potentially improving both safety and effectiveness by delivering more payload selectively to tumors. Avacta expects to initiate a Phase 1 clinical trial of AVA6103 in the first quarter of 2026 and plans to present the dataset at an upcoming scientific congress and submit it for peer-reviewed publication."

Gmcc

CC quoted in article - courtesy once again to Stonks

https://x.com/JStonker/status/2029528613943497029/photo/1

https://www.pharmaceutical-technology.com/features/targeted-therapies-chemotherapy-cancer-treatment-paradigm/?cf-view

"Targeted therapies to join chemo as oncology treatment backbone

Experts agree that combination approaches, which may or may not include chemotherapy, will drive improved patient outcomes in oncology.

Annabel Kartal Allen

March 5, 2026"

Gmcc

Https://x.com/search?q=%23AVCT&src=typeahead_click&f=live

CC "

Christina Coughlin

@coughlin582

·

4m

We had a great time in Boston this week. Many good conversations about #AVCT here at the TD Cowen Healthcare Conference

#HopeWithoutCompromise"

Gmcc

Avacta still using old slide headers -spotted by Stonks - Mind you deal with Novartis would be ok .

"Avacta meets Novartis: Pre|CISION single and dual warheads"

https://avacta.com/wp-content/uploads/2026/03/Avacta-Cowen-presentation-pdf_final_04Mar2026.pdf

Gmcc

Also on Avacta website : Great presentation .

https://avacta.com/events-presentations/46th-annual-td-cowen-health-care-conference-in-boston/

Gmcc

Https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/LwUt6pCTp7n3eomJgfvTSA

Stonks seems to have live feed !

https://x.com/search?q=%23AVCT&src=typeahead_click&f=live

"“It’s always an important time to highlight the challenges that these patients go through, [acknowledge] the journey they’re on, and bring awareness to why we need better treatments in this [setting].”

TNBC patients opportunity to take part in Avacta clinical trials - ongoing /upcoming AVA6000 & AVA6103 treatments .

https://www.onclive.com/view/dr-kruse-on-the-significance-of-tnbc-day

https://avacta.com/pipeline/

Gmcc

Nice to see Avacta staff efforts rewarded ,

!Ruairidh EdwardsRuairidh Edwards

• 3rd+Verified • 3rd+

Associate Director, Clinical Science & Translational Medicine | Clinical Science & Biomarkers in OncologyAssociate Director, Clinical Science & Translational Medicine | Clinical Science & Biomarkers in Oncology

1d • 1 day ago • Visible to anyone on or off LinkedIn

Follow

I’m delighted to share that I’ve been promoted to Associate Director, Clinical Science & Translational Medicine at Avacta Therapeutics .

Over the past few years I’ve worked with fantastic colleagues across research and clinical development to integrate biomarker and clinical data into development strategy, something I enjoy doing every single day.

I’m incredibly grateful to everyone who’s supported, taught and challenged me along the way.

Looking forward to the next phase as our programmes continue to progress, with the ultimate aim of improving outcomes for patients."

Gmcc

Avacta confirmation

https://x.com/avacta/status/2028494606346711329

Avacta

@avacta

·

3m

Investors interested in accessing the presentation may view the replay of the presentation, which will be available after the event on the Investor Resources page of the Avacta website. #AVCT

Avacta

@avacta

Avacta CEO Christina Coughlin and CFO Brian Hahn will be in Boston this week for the 46th Annual TD Cowen Health Care Conference in Boston. The company will host investor meetings throughout the day on March 4, with a live presentation at 9:50 AM ET. #AVCT

3:36 PM · Mar 2, 2026

·

35

Views

Gmcc

Courtesy https://x.com/search?q=%23AVCT&src=typeahead_click&f=live

Date has changed : 4th March @ 9.50am -10,20amEST

-------

Previous RNS

@ Christina Coughlin, CEO and Brian Hahn, CFO of Avacta, will participate in the 46th Annual TD Cowen Health Care Conference in Boston on March 3, 2026. The company will host investor meetings throughout the day, with a live Company presentation at 9:10 AM ET. Investors interested in accessing the Company's presentation may view the replay of the presentation, which will be available after the event on the Investor Resources | Avacta Therapeutics site.

Christina Coughlin, CEO and Brian Hahn, CFO of Avacta, will participate in the 46th Annual TD Cowen Health Care Conference in Boston on March 3, 2026. The company will host investor meetings throughout the day, with a live Company presentation at 9:10 AM ET. Investors interested in accessing the Company's presentation may view the replay of the presentation, which will be available after the event on the Investor Resources | Avacta Therapeutics site.

Yes Monday, March 23 | 14:30–15:15 not next week !

Https://informaconnect.com/bioeurope-spring/agenda/2/#therapeutic-insights_charting-the-current-of-innovation-and-opportunity-in-oncology_14-30

FYI

Avacta Therapeutics

5m •

We’re excited to be heading to Lisbon for BIO-Europe Spring next week! Our CEO Christina Coughlin will be joining an expert panel on Monday, March 23 to discuss the latest innovation and opportunity shaping the oncology landscape, from precision medicine and immunotherapies to novel modalities and combination treatments.

📍 Panel: Charting the Current of Innovation and Opportunity in Oncology

📅 Monday, March 23 | 14:30–15:15

📌 Room: Sintra

#BIOEuropeSpring #Biotech #Biopharma #Oncology #LifeSciences

https://www.linkedin.com/company/avacta/posts/?feedView=all

Gmcc

Https://pharmadevicenews.com/avacta-aim-avct-fap-exd-data-challenges-enhertu-on-tumor-selectivity-ahead-of-phase-1-start/

Think author ADC fan -"The methodological choice here deserves more scrutiny than the headline numbers."

Article ignores any mention of AVA6000 positive patient clinical data /merits of using precision FAP technology + FDA approval to remove MTD requirement for ongoing trials . Also fails to recognise FDA experts have already approved IND filing for AVA6103 which is a kind of peer review + Candidate cancer tumours have been selected for phase one so no ambiguity .

Avacta RNS have stated "Avacta scientists plan to present these data at an upcoming scientific congress and submit to a peer-reviewed journal in the near future"

Anyway a different read Kind of challenges the validity of using synthetic comparator arm :

-------

"Christina Coughlin

@coughlin582

Our #AVCT team used creative and highly standard AI methods and data analysis systems/tools to recreate a dataset published by AZ scientists working on T-Dxd (Enhertu), a successful Antibody Drug Conjugate (ADC). These exact data were then compared to our FAP-Exd (AVA6103) data"

Gmcc

Courtesy stonks - Avacta presenting

Date: March 11, 2026 - 10:30 - 14:00 GMT

Location: The Studio, The Westworks, 195 Wood Lane, White City, London, W12 7FQ

https://www.crownbio.com/london-roadshow-26

Gmcc

RE: >500 Molecules - nicely explained

https://pbs.twimg.com/media/HCDfqioWsAAaaGU?format=jpg&name=large

Gmcc

@ stonks - appreciate your research always new info many thanks for sharing .

--------------

"stonks

@JStonker

·

2h

#AVCT - "a very successful delivery platform"

https://x.com/JStonker/status/2026726017700631004/photo/1

------------

"stonks

@JStonker

·

3h

Some #AVCT coverage published in 🇩🇪 this afternoon - I've not heard of this site before but it gets millions of visits per month in Germany and has a 'good' authority score according to SEMRush.

https://ad-hoc-news.de/boerse/news/ueberblick/avacta-aktie-vielversprechende-daten/68611691

https://x.com/search?q=%23AVCT&src=typeahead_click&f=live